Background: Consensus among dermatologists and rheumatologists in the diagnosis and assessment of musculoskeletal diseases in psoriasis (PsO) patients is needed. This study assesses characteristics of musculoskeletal pain in patients with PsO for the presence of psoriatic arthritis (PsA) and evaluation of a novel 16-item visual instrument (PsA-Disk). Methods: Data were collected from eight dermatological/rheumatological centres across Italy. Patients with PsO completed PEST (Psoriasis Epidemiology Screening Tool) and PsADisk questionnaires during the first visit. A rheumatological visit was performed to confirm the presence of PsA. Both validity and reliability of PsA-Disk were assessed. Results: A total of 573 patients with PsO were examined at the first visit, and 120 (21%) were diagnosed with PsA. Patients with PsA compared with patients with PsO (n = 119) presented statistically significant differences for: nail involvement, PEST score ⩾3, higher erythrocyte sedimentation rate (ESR), Nail Psoriasis Severity Index (NAPSI)-feet, NAPSI-(hands + feet) and PsA-Disk scores (73.9 ± 32.1 versus 58.1 ± 39.8, p < 0.001). Patients with PsA with knee arthritis had higher PsA-Disk scores (98.4 ± 26 versus 71.5 ± 31.9, p = 0.006) that were also correlated with number of swollen (r = 0.2, p < 0.05) and tender joints (r = 0.24, p = 0. Conclusion: PsA-Disk may be considered a valid novel instrument aiding both dermatologists and rheumatologists in the rapid detection and assessment of musculoskeletal disease characteristics.
Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory disease typically associated with psoriasis (PsO), involving peripheral joints, entheses, tendons and axial skeleton affecting 0.16-0.25% of the world population. [1] [2] [3] The prevalence of PsA in PsO patients varies from 6% to 41% based on different clinical settings. [4] [5] [6] [7] Diagnosis relies mainly on clinical evaluation and classification is based on CASPAR (ClASsification criteria for Psoriatic ARthritis), often used in epidemiological and research studies. 8 PsO and PsA have a strong impact on physical and mental functions, similar to that observed in other severe chronic diseases 9 with high levels of stress, poor self-esteem, increased rates of mood disorders and detrimental effects on social functioning, interpersonal relationships and productivity. 10 Patients with PsA may develop severe musculoskeletal involvement in addition to cutaneous signs, with a further negative impact on function and quality of life (QoL). 11, 12 A delay in the diagnosis of PsA is associated with adverse long-term outcome, such as progressive erosive and osteoproliferative joint damage and associated disabilities; the early detection of PsA instead can potentially prevent these significant complications. 13 The Group for Outcome Measures in Rheumatology (OMERACT), and for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) refined and assessed the different PsA domains in order to identify accurate, reliable and feasible activity measures for clinical trials and daily practice. 14 The OMERACT group originally proposed a core set of six core domains, represented by peripheral joint and skin activity, pain, patient global assessment (PGA), physical function, and health-related (HR)QoL. 15 This has since been updated to now include musculoskeletal disease activity, skin disease activity, fatigue, pain, PGA, physical function, HRQoL and systemic inflammation. 16 Concurrently, the GRAPPA highlighted that the assessment of PsA should include all major disease domains, including peripheral arthritis, axial disease, enthesitis, dactylitis, PsO, and nail disease. However, the characteristics of musculoskeletal pain and its impact on patients with PsA should also be examined. 17 In addition, disease activity and other potentially related conditions should also be considered, including cardiovascular disease, uveitis and inflammatory bowel disease. 17 A number of screening questionnaires [e.g. Toronto Psoriatic Arthritis Screen, Psoriasis Epidemiology Screening Tool (PEST), psoriatic arthritis screening and evaluation and Early ARthritis for Psoriatic patients (EARP)] used by dermatologists or general practitioners have been developed to identify PsO patients who refer symptoms suggestive of PsA. [18] [19] [20] [21] Although the PEST questionnaire was shown to have the highest area under the curve, it is limited by its simplicity. 22, 23 Frequently, these instruments are not systematically performed in daily clinical practice, probably due to the lack of time available in routine clinical practice. Another limitation of these tools is that they do not provide any information on the global impact of the musculoskeletal disease on patients with PsO. 24, 25 Therefore, a rapid and visually intuitive instrument is needed to screen and assess PsA in patients with PsO for dermatologists for a correct rheumatological referral. The aim of this study was to assess characteristics of musculoskeletal pain in patients with PsO for the presence of PsA and evaluation of a novel 16-item visual instrument (PsA-Disk) for the characterization and description of PsA clinical manifestations.
Materials and methods

Patients and study design
Data were collected prospectively from eight dermatological/rheumatological centres in Italy.
Consecutive adult patients with PsO at their first dermatological visit from September 2017 to March 2018 presenting with musculoskeletal pain were invited to complete both PEST 19 and PsA-Disk questionnaires.
Inclusion criteria were: male and female patients aged ⩾18 years, with a diagnosis of PsO and presence of musculoskeletal pain but without a previous diagnosis of PsA. Exclusion criteria were: patients diagnosed with PsA, patients with PsO treated with systemic steroids, nonsteroidal antiinflammatory drugs (NSAIDs), conventional systemic disease-modifying antirheumatic drugs 
Clinical measures
PsO severity was measured using the Psoriasis Area and Severity Index (PASI), 26 the Physician Global Assessment 25 and Body Surface Area (BSA). 27 Nail disease activity was measured using the Nail Psoriasis Severity Index (NAPSI). 28 Joint disease activity was assessed using the number of tender and swollen joint count (68 joints were assessed for tenderness and 66 joints were assessed for swelling), the 44-joint-count Disease Activity Score (DAS-44), Disease Activity in Psoriatic Arthritis (DAPSA), composite psoriatic arthritis disease activity index (CPDAI), the visual analogue scale (pain-VAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). [29] [30] [31] The presence or absence of axial involvement and number of fingers/toes with dactylitis were also recorded. Axial involvement was defined in patients who had a physician-reported presence of spinal involvement at enrolment, based on clinical judgment of clinical features thought to be representative of active inflammatory spondylitis, or radiographs or magnetic resonance imaging showing sacroiliitis. 32 Enthesitis was assessed by physical examination as painful (positive confirmation) or without pain (negative confirmation) according to the expanded Leeds index. The following entheses were bilaterally evaluated: lateral epicondyle, medial femoral condyle, Achilles tendon insertion, insertion of quadriceps tendon on the superior pole of the patella, proximal insertion of the patellar tendon on the inferior pole of the patella and the insertion of the plantar fascia on the calcaneus, as previously described. 33 Laboratory tests included erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). ESR was measured by the Westergren method and CRP was determined using standard commercial kits. Data on demographic and anamnestic characteristics and concomitant diseases were also recorded.
PsA-Disk
The PsA-Disk is a visual intuitive instrument, aimed to describe the musculoskeletal symptoms of patients with PsA. It consists of 16 questions developed using (dermatology and rheumatology) focus groups and a Delphi procedure 34 exploring the presence and characteristics of pain in different body sites and quality of sleep [ Figure  1 
Validation and cut-off scores of PsA-Disk
The overall and item-specific reliability of the PsA-Disk questionnaire was evaluated for internal consistency and stability (test-retest of 45 patients within a time-span of 3 days) using the Cronbach's alpha and the intraclass correlation (ICC), respectively. Internal consistency ranges between 0-1. A commonly accepted rule of thumb is that an α of 0.6-0.7 indicates acceptable reliability, and 0.8 or higher indicates good reliability. We used the receiving operating characteristics curve with Youden's J statistic to assess the cut-off value of the total PsA-Disk score that better predicts clinical diagnosis of PsA (Supplemental Material Figure 1 ). Based on this cut-off value (PsA-Disk score = 44: sensitivity, 87.2%; specificity, 46.4%; J index = 0.34; Supplemental Material Table 1 ), we assessed the criterion validity of the PsA-Disk evaluating its agreement with Table 1 ).
Association between PsA-Disk scores and rheumatological variables
The impact of a range of rheumatological disease activity measures (presence or absence of a specific feature) on PsA-Disk scores was next evaluated in patients with PsA (Table 2 ). This analysis revealed that patients presenting with knee joint involvement had significantly higher PsA-Disk scores (98.4 ± 26 versus 71.5 ± 31.9, p = 0.006) compared with patients without knee joint involvement (Table 2) . Furthermore, patients presenting with oligoarthritis (⩾5 painful joints) had significantly higher PsA-Disk scores compared with those without (81.4 ± 32.8 versus 66.4 ± 30, p = 0.023). Stratifying DAPSA scores into low, moderate and high disease activity was also found to be associated with increasing PsA-Disk scores (Table 2) . Patients with axial involvement also had a higher PsA-Disk score, although this difference did not attain statistical significance (Table 2) . We observed several positive correlations between disease activity and PsA-Disk score in patients with PsA including number of swollen and tender joints, patient and physician pain-VAS, PGA-VAS, physician-HAQ, DAS-44 and DAPSA (Table 3) . However, CRP and ESR were not correlated with PsA-Disk score (Table 3) .
Impact of clinical characteristics on PsA-Disk 16-item visual output
Examples of the powerful visual use of this instrument can be seen in Figure 2 . Differences in clinical characteristics across the 16 items can be visualised quickly. Following subgroup analysis, 
Validation and cut-off scores of PsA-Disk
Overall, the reliability of the PsA-Disk questionnaire was excellent for both internal consistency (Cronbach's alpha = 0.90) and stability [ICC = 0.98, 95% confidence interval (CI): 0.97-0.99; Table 4 ]. In particular, according to test-retest, we observed a good stability (ICC > 0.8) for all items, except shoulder pain (ICC = 0.64, 95% CI: 0.39-0.80; Table 4 ). The analysis of criterion validity showed a moderate level of agreement between PsA-Disk and PEST (Cohen's kappa = 0.46), while the construct validity appeared appropriate [PsA + patients: median PsA-Disk score (IQR) = 71 (50-96); PsA-patients: median PsA-Disk score (IQR) = 50 (20-90); p < 0.001].
Discussion
In this multicentre study, we validated the PsADisk in a large group of patients with PsO from eight dermatological/rheumatological centres across Italy. We demonstrated that the PsA-Disk can be used rapidly and easily to evaluate the characteristics of musculoskeletal symptoms in patients with PsA.
The present study also evaluated the prevalence of PsA in patients with PsO. Indeed, we demonstrated that 48.7% (279/573) of patients with PsO with joint pain were diagnosed with PsA (prevalence of 21% based on all 573 patients who presented at their first visit). This prevalence is higher than would be expected, even in a secondary care setting 7 and is likely due to the fact that the eight centres that participated in this study already routinely undertook shared dermatologyrheumatology clinics, therefore raising their level of expertise and facilitating diagnosis.
The phenotypic characteristics of patients with PsO and PsA were also different: a greater proportion of patients with PsA had localized PsO at the limbs or trunk or face and more nail PsO. Moreover, a significantly higher proportion of patients who were PsA-positive had elevated PEST scores, ESR, nail PsO, NAPSI and PsADisk scores compared with patients who were PsA-negative. PsA-Disk scores were also positively correlated with tender and swollen joints, physician-HAQ, patient-and physician-VAS Table 4 . Reliability of PsA-Disk for 16 items (internal consistency and stability). (pain), PGA-VAS, DAS-44 and DAPSA. Results of this first phase developmental study are particularly promising in that a range of classical disease activity measures were significantly correlated with PsA-Disk scores.
Item
While this questionnaire cannot be used independently to diagnose PsA, we have found that using a PsA-Disk cut-off value of ⩾44 could be used to identify and monitor patients with PsA. The internal consistency was also very satisfactory, with Cronbach's alpha value of 0.90 and internal stability of 0.98.
The PsA-Disk offers potential advantages over already existing instruments and tools used to evaluate PsA. The relative simplicity of the PEST questionnaire is regarded as a weakness, since this tool cannot detect pure axial forms of the disease. 23 The PsA-Disk questionnaire was specifically designed to address this limitation, by including specific items for neck and back pain. In addition, many other instruments are completed by the physician, whereas the PsADisk was designed to be completed by the patient, promoting discussion between patient and specialist, often neglected in a medical consultation. Improved communication between patient and physician may in turn lead to improved adherence to treatment. Furthermore, implementation of the PsA-Disk will also promote discussion between dermatologist and rheumatologist, particularly in clinics where a dermatology-rheumatology multidisciplinary approach is not already established, in turn facilitating early referral and early diagnosis.
Another potential benefit afforded from the PsADisk is that it is a visual instrument. Answers to the 16 questions yield scores are graphically displayed as a polygon implying that both patient and physician can literally observe changes over the course of the disease. The PsA-Disk is also a simple and intuitive instrument allowing the patient to complete it rapidly.
This study has some limitations that need to be highlighted. Although we observed some significant associations between disease activity measures and PsA-Disk scores, a higher sample size may have revealed additional significant associations that were not detectable with the current sample size. Our analysis was cross-sectional. It would be interesting to explore the use of this instrument to monitor disease progression or effect of therapeutic intervention on prognosis.
Conclusion
In summary, the PsA-Disk is a novel instrument, which can facilitate in the detection and assessment of disease severity in patients with PsA, particularly in dermatology clinics where joint dermatology-rheumatology clinics are not routinely undertaken. The main advantages of this instrument are the low number of items, the visual nature of the results, and the fact that it is completed together by the patient and dermatologist/ rheumatologist. Future studies will be aimed to evaluate the discriminatory power of this instrument in clinical trials and monitoring of patient.
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